HC Wainwright Predicts Journey Medical FY2026 Earnings

Journey Medical logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised its FY2026 EPS forecast for Journey Medical to a loss of $0.26 per share from a projected loss of $0.29, while maintaining a Buy rating and $13 price target. The firm forecasts the company will turn profitable by FY2028.
  • Journey Medical’s latest quarterly results missed expectations: it reported a $0.05-per-share loss versus the $0.02 consensus loss, and revenue of $18.97 million versus expectations of $20.32 million.
  • Analyst views are mixed, with two Buy and two Sell ratings; MarketBeat’s consensus rating is Hold, with an average price target of $13.
  • MarketBeat previews top five stocks to own in December.

Journey Medical Corporation (NASDAQ:DERM - Free Report) - HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for Journey Medical in a research note issued on Friday, November 13th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of ($0.26) per share for the year, up from their prior estimate of ($0.29). HC Wainwright currently has a "Buy" rating and a $13.00 target price on the stock. The consensus estimate for Journey Medical's current full-year earnings is ($0.13) per share. HC Wainwright also issued estimates for Journey Medical's FY2028 earnings at $0.31 EPS, FY2029 earnings at $0.47 EPS and FY2030 earnings at $0.51 EPS.

Journey Medical (NASDAQ:DERM - Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.03). The firm had revenue of $18.97 million for the quarter, compared to analysts' expectations of $20.32 million. Journey Medical had a negative return on equity of 16.15% and a negative net margin of 7.34%.

A number of other equities research analysts have also weighed in on the stock. B. Riley Financial restated a "buy" rating and issued a $13.00 price objective (down from $15.00) on shares of Journey Medical in a report on Friday. Zacks Research downgraded shares of Journey Medical from a "hold" rating to a "strong sell" rating in a research note on Thursday, November 12th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Journey Medical in a research note on Thursday, October 15th. Finally, Wall Street Zen lowered Journey Medical from a "buy" rating to a "hold" rating in a report on Saturday, October 17th. Two analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $13.00.

View Our Latest Stock Report on Journey Medical

Journey Medical Stock Performance

Shares of Journey Medical stock opened at $3.70 on Tuesday. The company has a current ratio of 1.59, a quick ratio of 1.41 and a debt-to-equity ratio of 0.64. Journey Medical has a 52-week low of $3.64 and a 52-week high of $9.56. The company has a 50 day moving average of $5.81 and a 200 day moving average of $6.45.

Hedge Funds Weigh In On Journey Medical

Hedge funds have recently added to or reduced their stakes in the stock. Jump Financial LLC acquired a new stake in Journey Medical during the third quarter worth approximately $81,000. Marshall Wace LLP boosted its holdings in shares of Journey Medical by 38.9% in the 3rd quarter. Marshall Wace LLP now owns 194,311 shares of the company's stock valued at $1,329,000 after buying an additional 54,468 shares in the last quarter. First Eagle Investment Management LLC acquired a new position in shares of Journey Medical in the 3rd quarter valued at $3,305,000. Allegiance Financial Group Advisory Services LLC acquired a new position in shares of Journey Medical in the 3rd quarter valued at $68,000. Finally, Salem Investment Counselors Inc. grew its position in shares of Journey Medical by 21.0% in the 3rd quarter. Salem Investment Counselors Inc. now owns 35,319 shares of the company's stock valued at $242,000 after buying an additional 6,119 shares during the last quarter. 7.25% of the stock is currently owned by hedge funds and other institutional investors.

Journey Medical Company Profile

(Get Free Report)

Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and marketing prescription treatments for dermatological conditions. Founded in 2014 and based in Scottsdale, Arizona, the company primarily serves the U.S. market. Its portfolio includes treatments for conditions such as acne, rosacea, excessive underarm sweating and fungal skin infections. Products include Amzeeq and Zilxi, topical minocycline therapies; Qbrexza, a topical treatment for primary axillary hyperhidrosis; and the oral rosacea treatment Emrosi.

Featured Articles

Earnings History and Estimates for Journey Medical (NASDAQ:DERM)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Journey Medical Right Now?

Before you consider Journey Medical, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Journey Medical wasn't on the list.

While Journey Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines